{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:15:32Z","timestamp":1785842132289,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ygyno.2011.11.042","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T14:34:20Z","timestamp":1323268460000},"page":"136-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia"],"prefix":"10.1016","volume":"125","author":[{"given":"H.J.","family":"Mackay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Buckanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hoskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Polintan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.11.042_bb0005","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2005.01.041","article-title":"Systemic therapy for advanced uterine sarcoma: a systematic review of the literature","volume":"97","author":"Kanjeekal","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0010","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-tissue sarcomas in adults","volume":"353","author":"Clark","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0015","first-page":"295","article-title":"The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases","volume":"23","author":"Gadducci","year":"2002","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0020","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/ijgc-00009577-200211000-00001","article-title":"Uterine carcinosarcomas (malignant mixed Mullarian tumors) are metaplastic carcinomas","volume":"12","author":"McCluggage","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.2000.6001","article-title":"A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study","volume":"79","author":"Sutton","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2006.06.4907","article-title":"Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: A Gynecologic Oncology Group study","volume":"25","author":"Homesley","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0035","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1200\/JCO.2009.26.8326","article-title":"A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"28","author":"Powell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0040","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0002-9378(92)91671-V","article-title":"Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"166","author":"Sutton","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0045","first-page":"1303","article-title":"Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study","volume":"71","author":"Slayton","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0050","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ygyno.2004.11.036","article-title":"Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2011.11.042_bb0060","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ygyno.2011.08.016","article-title":"Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers","volume":"123","author":"Sanfilippo","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0065","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.10028","article-title":"Trabectedin in the treatment of advanced uterine leiomyosarcomas: results of a pooled analysis of five single-agent phase II studies using the recommended dose","volume":"28","author":"Judson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0080","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/cncr.20819","article-title":"Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma","volume":"103","author":"Mitsuhashi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0085","doi-asserted-by":"crossref","first-page":"7487","DOI":"10.1158\/1078-0432.CCR-07-1017","article-title":"Clinical and biological significance of vascular endothelial growth factor in endometrial cancer","volume":"13","author":"Kamat","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0090-8258(03)00332-9","article-title":"A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets","volume":"90","author":"Ramondetta","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/ijgc-00009577-200503000-00024","article-title":"Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma","volume":"15","author":"Arita","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0110","first-page":"3591","article-title":"Expression of vascular endothelial growth factor and its receptor, KDR\/Flk-1, in soft tissue sarcomas","volume":"25","author":"Pakos","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0115","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2007.05.013","article-title":"A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study","volume":"106","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0120","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0125","first-page":"199s","article-title":"Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors","volume":"23","author":"Dupont","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0135","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft tissue sarcoma","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2011.11.042_bb0140","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s13277-010-0138-1","article-title":"Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers","volume":"32","author":"Koivisto-Korander","year":"2011","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0145","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2009.09.011","article-title":"Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"115","author":"Hensley","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0150","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ygyno.2003.11.023","article-title":"Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study","volume":"92","author":"Look","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0155","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2010.01.013","article-title":"A phase II study of sorafenib in advanced uterine carcinoma\/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia","volume":"117","author":"Nimeiri","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0165","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ygyno.2010.01.002","article-title":"Efficacy and safety of imatinib mesylate (Gleevec\u00ae) and immunohistochemical expression of c-Kit and PDGFR-\u03b2 in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus","volume":"117","author":"Huh","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0175","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ygyno.2010.03.024","article-title":"A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study","volume":"118","author":"Miller","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/gyno.1994.1081","article-title":"A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"53","author":"Sutton","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0185","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/JTO.0b013e3181e2f7fb","article-title":"A multicenter, phase 2 study of vascular endothelial growth factor Trap (aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung","volume":"10","author":"Leighl","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ygyno.2011.11.042_bb0195","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.urology.2010.04.025","article-title":"Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial","volume":"76","author":"Twardowski","year":"2010","journal-title":"Urology"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811009619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811009619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:30:23Z","timestamp":1758771023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811009619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0090825811009619"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.11.042","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.11.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}